特宝生物拟发可转债15.33亿加码主业，2025年业绩快报显示营收净利双增

Group 1 - The company plans to issue convertible bonds to raise a total of up to 1.533 billion yuan for new drug research and development projects [1][2] - The company reported a revenue of 3.696 billion yuan for 2025, representing a year-on-year growth of 31.18% [3] - The net profit attributable to the parent company for 2025 was 1.038 billion yuan, showing a year-on-year increase of 25.39% [3] Group 2 - The revenue growth is primarily driven by stable sales of key product Paigebin and the launch of new product Yipei [3] - The funds raised from the bond issuance will also support the construction of a biotechnology innovation integration center and the expansion of innovative drug production [2]